BiotechTube
COBIK

COBIK

Ljubljana, Europe - Other· Est.
cobik.si
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

COBIK is a European biotech firm with a dual business model combining contract services with proprietary therapeutic development. Its service arm offers expertise in bioprocess development, scale-up, non-GMP manufacturing of biologics (pDNA, proteins, VLPs, viruses), and project management for international consortia. The company's internal pipeline targets antibiotic-resistant infections and emerging viral diseases through phage therapy and vaccine candidates, currently in pre-clinical stages. COBIK has also demonstrated an ability to spin out ventures, as seen with Sferogen (vaccines) and Tech4Meat (cultured meat).

Infectious DiseaseAntimicrobial Resistance

Technology Platform

Bioprocess development, scale-up, and instrumentation platform for complex biologics; applied to develop bacteriophage cocktails and viral vaccines using bioengineering and molecular biology tools.

Opportunities

The growing global crisis of antimicrobial resistance (AMR) creates a significant unmet need and renewed interest in phage therapy as an alternative to traditional antibiotics.
Additionally, the post-pandemic emphasis on pandemic preparedness and versatile vaccine platforms presents a major opportunity for its viral vaccine pipeline.

Risk Factors

The internal therapeutic pipeline is at an early pre-clinical stage, carrying high technical and regulatory risk.
The hybrid business model (services + therapeutics) may strain resources.
As a smaller European player, it faces competition from larger CDMOs and biopharma companies for clients, talent, and funding.

Competitive Landscape

In services, COBIK competes with other European CDMOs and bioprocess development consultancies, differentiating through its Center of Excellence status and project management expertise. In therapeutics, it competes in the nascent phage therapy space against other biotechs like Armata Pharma and Adaptive Phage Therapeutics, and in vaccines against numerous established and startup entities.

More companies in Europe - Other →